Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 clinical study of influenza vaccine - Emergex Vaccines

Trial Profile

A phase 1 clinical study of influenza vaccine - Emergex Vaccines

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Influenza vaccine Emergex Vaccines (Primary)
  • Indications Influenza A virus infections
  • Focus Adverse reactions

Most Recent Events

  • 17 Oct 2024 According to Emergex Vaccines media release, Emergex Vaccines has changed its name to Gylden Pharma Limited.
  • 22 Aug 2024 According to Emergex Vaccines media release, Emergex is set to advance its first-in-class influenza vaccine into the clinic, with Phase I trials anticipated to begin in the first half of 2025.
  • 15 Jan 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top